Cargando…

Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

BACKGROUND: Canagliflozin is a sodium glucose co-transporter (SGLT) 2 inhibitor in clinical development for the treatment of type 2 diabetes mellitus (T2DM). METHODS: (14)C-alpha-methylglucoside uptake in Chinese hamster ovary-K cells expressing human, rat, or mouse SGLT2 or SGLT1; (3)H-2-deoxy-d-gl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Yin, Arakawa, Kenji, Ueta, Kiichiro, Matsushita, Yasuaki, Kuriyama, Chiaki, Martin, Tonya, Du, Fuyong, Liu, Yi, Xu, June, Conway, Bruce, Conway, Jamie, Polidori, David, Ways, Kirk, Demarest, Keith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280264/ https://www.ncbi.nlm.nih.gov/pubmed/22355316 http://dx.doi.org/10.1371/journal.pone.0030555

Ejemplares similares

Beneficial Effects of Canagliflozin in Combination with Pioglitazone on Insulin Sensitivity in Rodent Models of Obese Type 2 Diabetes
por: Watanabe, Yoshinori, et al.
Publicado: (2015)

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
por: Erondu, Ngozi, et al.
Publicado: (2015)

Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes
por: Sha, Sue, et al.
Publicado: (2014)

Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
por: Polidori, David, et al.
Publicado: (2013)

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial
por: Wada, Takashi, et al.
Publicado: (2021)

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

Thresholds of glycemia, insulin therapy, and risk for severe retinopathy in premature infants: A cohort study
por: Kermorvant-Duchemin, Elsa, et al.
Publicado: (2020)

Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study
por: Osonoi, Takeshi, et al.
Publicado: (2018)

Canagliflozin – Beginning of the journey
por: Pandey, Sunil Kumar, et al.
Publicado: (2014)

Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study
por: Sha, S., et al.
Publicado: (2015)

Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus
por: Tanaka, Hiroyuki, et al.
Publicado: (2016)

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes
por: Polidori, David, et al.
Publicado: (2014)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

The Threshold of Admission Glycemia as a Predictor of Adverse Events in Diabetic and Non-Diabetic Patients with Acute Coronary Syndrome
por: Garadah, Taysir S., et al.
Publicado: (2009)

Bradykinin, insulin, and glycemia responses to exercise performed above and below lactate threshold in individuals with type 2 diabetes
por: Asano, R.Y., et al.
Publicado: (2017)

Crystal structure of canagliflozin hemihydrate
por: Liu, Kai-Hang, et al.
Publicado: (2016)

Diabetes Treatment and Measures of Glycemia
por: Bloomgarden, Zachary T.
Publicado: (2009)

COVID-19, colchicine and glycemia
por: Ilias, Ioannis, et al.
Publicado: (2021)

Thresholds of Glycemia and the Outcomes of COVID-19 Complicated With Diabetes: A Retrospective Exploratory Study Using Continuous Glucose Monitoring
por: Shen, Yun, et al.
Publicado: (2021)

Patient profiling in diabetes and role of canagliflozin
por: Amblee, Ambika
Publicado: (2014)

Prolonged diabetic ketoacidosis associated with canagliflozin
por: Sloan, Gordon, et al.
Publicado: (2018)

Repurposing Canagliflozin to target brain aging
por: Jayarathne, Hashan, et al.
Publicado: (2023)

Patterns of Glycemia in Normal Pregnancy: Should the current therapeutic targets be challenged?
por: Hernandez, Teri L., et al.
Publicado: (2011)

Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model
por: Nishinarita, Ryo, et al.
Publicado: (2021)

Diabetes and Other Disorders of Glycemia in a Rural South African Community: Prevalence and associated risk factors
por: Motala, Ayesha A., et al.
Publicado: (2008)

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
por: Mahaffey, Kenneth W., et al.
Publicado: (2018)

CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
por: Woo, Vincent, et al.
Publicado: (2018)

Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes
por: Takahara, Mitsuyoshi, et al.
Publicado: (2020)

Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin
por: Polidori, David, et al.
Publicado: (2018)

ACCORD Glycemia Results Continue to Puzzle
por: Boyko, Edward J.
Publicado: (2010)

Management of Glycemia in Acute Febrile Illness
por: Kalra, Sanjay, et al.
Publicado: (2017)

Assessment of glycemia in chronic kidney disease
por: Hassanein, Mohamed, et al.
Publicado: (2022)

Canagliflozin in Type 1 Diabetes: A Case Series of Patient Outcomes in a Diabetes Clinic
por: Roberts, Tori Marie, et al.
Publicado: (2019)

Caldera collapse thresholds correlate with magma chamber dimensions
por: Geshi, Nobuo, et al.
Publicado: (2023)

Arginine vasopressin: Direct and indirect action on metabolism
por: Yoshimura, Mitsuhiro, et al.
Publicado: (2021)

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Efficacy and Safety of Canagliflozin in Kidney Transplant Patients
por: Shah, Mita, et al.
Publicado: (2019)

Effects of canagliflozin on human myocardial redox signalling: clinical implications
por: Kondo, Hidekazu, et al.
Publicado: (2021)

Nontraditional Markers of Glycemia: Associations with microvascular conditions
por: Selvin, Elizabeth, et al.
Publicado: (2011)

Drug-drug Interaction-related Uncontrolled Glycemia
por: Hammad, Mohamed Anwar, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lut4jgsutd2o93tu0vo62fnfbb